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Mycobacterium tuberculosis Whole Genome Sequences 
From Southern India Suggest Novel Resistance 
Mechanisms and the Need for Region-Specific Diagnostics
Abigail L. Manson,1,a Thomas Abeel,1,2,a James E. Galagan,3,4,a Jagadish Chandrabose Sundaramurthi,5 Alex Salazar,1,2 Thies Gehrmann,2  
Siva Kumar Shanmugam,5 Kannan Palaniyandi,5 Sujatha Narayanan,5 Soumya Swaminathan,5,b and Ashlee M. Earl1,b
1Broad Institute of MIT and Harvard, Cambridge, Massachusetts; 2Delft Bioinformatics Lab, Delft University of Technology, The Netherlands; 3Department of Biomedical Engineering, and 4National 
Emerging Infectious Diseases Laboratory, Boston University, Massachusetts; and 5National Institute for Research in Tuberculosis, New Delhi, India
Background. India is home to 25% of all tuberculosis cases and the second highest number of multidrug resistant cases world-
wide. However, little is known about the genetic diversity and resistance determinants of Indian Mycobacterium tuberculosis, particu-
larly for the primary lineages found in India, lineages 1 and 3.
Methods. We whole genome sequenced 223 randomly selected M. tuberculosis strains from 196 patients within the Tiruvallur 
and Madurai districts of Tamil Nadu in Southern India. Using comparative genomics, we examined genetic diversity, transmission 
patterns, and evolution of resistance.
Results. Genomic analyses revealed (11) prevalence of strains from lineages 1 and 3, (11) recent transmission of strains among 
patients from the same treatment centers, (11) emergence of drug resistance within patients over time, (11) resistance gained in an 
order typical of strains from different lineages and geographies, (11) underperformance of known resistance-conferring mutations 
to explain phenotypic resistance in Indian strains relative to studies focused on other geographies, and (11) the possibility that 
resistance arose through mutations not previously implicated in resistance, or through infections with multiple strains that confound 
genotype-based prediction of resistance.
Conclusions. In addition to substantially expanding the genomic perspectives of lineages 1 and 3, sequencing and analysis of 
M. tuberculosis whole genomes from Southern India highlight challenges of infection control and rapid diagnosis of resistant tuber-
culosis using current technologies. Further studies are needed to fully explore the complement of diversity and resistance determi-
nants within endemic M. tuberculosis populations.
Keywords. Indo-Oceanic lineage; EAI lineage; CAS lineage; India; drug resistance. 
India has the largest number of tuberculosis patients world-
wide, accounting for over 25% of cases [1]. Drug resistant forms 
of Mycobacterium tuberculosis, the causative agent of tubercu-
losis, are rapidly spreading in India. These contribute to India 
having the second highest number of multi-drug resistant cases 
of tuberculosis (MDR-TB) [1], resistant to both isoniazid and 
rifampicin. Despite the presence of over 2 million tuberculosis 
cases in India, little is known about the genetic diversity [2] and 
drug resistance determinants of Indian M. tuberculosis [3].
India stands out as being home to primarily M. tuberculo-
sis lineages 1 (Indo-Oceanic or EAI lineage) and 3 (Central 
Asian or CAS lineage) [4], which occur at substantially lower 
frequency elsewhere. Lineages 2 (East Asian or Beijing) and 
4 (Euro-American) are most common in Europe, Africa, and 
many other parts of the world [4–6]. Within India, lineage 3 
predominates in the North and Northwest, whereas lineage 1 
is common in the South but is found at low frequency in other 
parts of the country [3, 7–9]. In contrast, lineage 2 has been 
reported at similar prevalence throughout India (17%), though 
it does predominate in some Northeast states [7].
Drug-resistant M. tuberculosis poses a threat because of low 
cure rates. In India, the rate of MDR-TB is 2–3% among new 
cases and 12–17% among reinfections [10] (similar to the global 
averages of 3.3% and 20%, respectively [1]). Further, about 4% of 
tuberculosis patients have XDR-TB [1], defined as MDR-TB with 
additional resistance to any fluoroquinolone and at least 1 of the 
second-line injectable drugs [11]. Rates of isoniazid resistance 
are much higher (10–15% among new and 30–40% among rein-
fections) and lead to poor treatment outcomes when associated 
with resistance to other first-line drugs. Thus, understanding of 
the evolution and determinants of drug resistance is essential to 
inform development of accurate and timely diagnostics [12].
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Recent whole genome sequencing studies have brought us 
closer to the goal of defining the complete catalog of drug resist-
ance in M. tuberculosis [13–15]. Although recent reports suggest 
that current mutation sets can account for the majority of pheno-
typic resistance in other parts of the world [16–19], such efforts 
have not yet included large-scale sequencing studies from India, 
where M.  tuberculosis lineages are known to vary from other 
global regions. Previous work has shown that Indian M. tubercu-
losis strains contain unique drug resistance mutations [20, 21], and 
that drug resistance patterns can vary among different lineages in 
India. For example, lineage 2 strains are more frequently MDR 
than lineage 1 or 3 strains [7, 22–25], and lineage 3 strains have 
been reported as more resistant than lineage 1 strains [7, 8, 26].
In this study, we sequenced 223 randomly selected strains 
from 196 patients within the Tiruvallur and Madurai Districts 
in Southern India. Through this effort, we extensively expanded 
the sampled diversity of lineages 1 and 3, leading to a better 
understanding of their genetic composition, including the 
determinants of drug resistance. We also examined the contri-
butions of transmission versus de novo acquisition of resistance 
mutations, as well as the order in which drug resistance muta-
tions were acquired. Finally, we examined the ability of existing 
mutation sets to predict phenotypic drug resistance and identi-
fied cases of unexplained drug resistance.
METHODS
Between 1999 and 2005, 27 M. tuberculosis strains were isolated 
for sequencing from unique patients in Madurai and 196 strains 
from 169 unique patients in Tiruvallur. The sample set included 
data from 154 males and 42 females with median age 39 ± 
14.5 years. For each strain, resistance to isoniazid, ethambutol, 
rifampicin, and streptomycin was determined. Sequencing data 
were submitted to the Sequence Read Archive under BioProject 
PRJNA235851. See Detailed Methods.
RESULTS
In order to examine genetic features of M. tuberculosis strains 
from Southern India, we generated high-quality whole genome 
sequences for 223 isolates (Table  1; Supplementary Table  1). 
Within our data set, phenotypic drug resistance, including 
MDR-TB, was not significantly associated with relapse, gen-
der, smoking or drinking (Fisher exact test, P > .05), even after 
correcting for over-representation from related same-patient 
isolates (see Methods). HIV status was only known for strains 
from Madurai, all of which were HIV positive, and only 5 of 
which were drug resistant (Table S1). We did not detect a signif-
icant association between strains from HIV-positive hosts and 
MDR or drug resistance though sample size was small.
Newly Sequenced Strains Expand the View of Genetic Diversity in 
Lineage 1
Using whole genome data, we constructed a phylogenetic tree 
and used digital spoligotyping (see Methods) to determine lin-
eages and spoligotypes (Supplementary Figures 1–2). Lineage 
1 strains dominated among newly sequenced isolates (Table 1), 
representing 141 (70%) of strains after correcting for over-rep-
resentation from related same-patient isolates. The relative 
abundances of lineages 1 and 3 were in agreement with earlier 
epidemiological observations [2, 3].
To place our strains within a global context, we constructed a 
phylogeny combining genomic data from newly sequenced strains 
with a previously published set of sequences from 243 globally 
diverse M. tuberculosis isolates [4] (Figure 1). Although lineage 1 and 
3 isolates from the published Comas study were phylogenetically 
intermingled with newly sequenced strains, the average distance 
between a new strain and its closest relative from the Comas set 
was 313 single-nucleotide polymorphisms (SNPs) (range: 71–833), 
representing an average divergence of >500  years (range: 118–
2276 years) (see Detailed Methods) [27]. In contrast, we observed 
deeply branching clusters composed solely of Indian strains, with 
many strains having few or no SNP differences (average 147 SNPs, 
range 0–810 SNPs, and representing an average divergence time of 
245 years with times ranging from 0 to 2,700 years). Based on the 
number of unique SNPs, the new genomic data from lineage 1 and 
3 isolates roughly doubled the known genetic diversity within these 
lineages (Supplementary Table 2).
Recent Transmission of Regionally Localized Strains
In addition to revealing close relationships among isolates from 
this study, the phylogeny indicated that recent transmission of 
strains was occurring among patients from the same and not dif-
ferent regions. To examine this more systematically, we clustered 
all strains from this study into “clonal groups” having ≤10 SNP 
Table  1. Summary of strain information for the set of 201 strains, 
after removing highly similar strains found within the same patient  
A) Distribution of strains with resistant and susceptible phenotypes for 
each of the four drugs tested.
Drug No. of resistant strains No. of susceptible strains
Isoniazid 36 (18%) 162 (82%)
Ethambutol 5 (3%) 193 (97%)
Rifampicin 12 (6%) 186 (94%)
Streptomycina 16 (9%) 171 (91%)
aFor streptomycin, an additional 11 strains did not have DST information for this drug
b198 of the 201 strains had DST information and are included in this table. The remaining 3 
strains did not have associated metadata.
B) Distribution of strains across the 4 lineages.
Lineage No. of strains
LIN-1 (EAI) 141 (70%)
LIN-2 (Beijing) 22 (11%)
LIN-3 (CAS) 32 (16%)
LIN-4 (Euro-American) 6 (3%)
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differences (see Methods), a threshold previously used to define 
recent transmission [17, 28]. Six of the 22 clonal groups (D28, 
D15, D30, D1, D8, and M4) contained strains from more than 1 
patient (Figure 2; Table 2), and none contained strains from both 
Madurai and Tiruvallur. Instead, strains from each of these clones 
were from patients reporting to the same treatment center, indi-
cating recent transmission was highly localized. In all but 1 case, 
patients having the same clone were infected with a susceptible 
strain. In the exceptional clone, M4 (Figure 2), we observed that 
an isoniazid monoresistant strain from patient 54 belonged to the 
same clone as three isoniazid and rifampicin-resistant strains iso-
lated from patient 97 more than 8 months later, indicating that a 
strain from this clonal group likely acquired rifampicin resistance 
during this time period; however, resistance could have occurred 
earlier in either patient or in an unsampled individual.
The Order in Which Drug Resistance Arises Among Southern Indian 
Tyberculosis is Similar to Other Global Regions
Our strain collection was enriched for drug resistant iso-
lates, as compared to the overall incidence of drug-resistant 
M.  tuberculosis in India (see Methods). Isoniazid resistant 
strains were most common (36 strains; Table  1a), consistent 
with previous observations from other global regions [29, 30]. 
Using a parsimony-based analysis (see Methods), we deter-
mined that resistance to isoniazid arose 33 independent times 
across the phylogeny. For 4 isoniazid/rifampicin pairs of resist-
ance arisals across the nodes of our phylogeny, we had suffi-
ciently dense sampling to determine relative ordering. In all 4 
cases, isoniazid arose first. Although there were only a small 
number of resistance pairs for which we could determine the 
order, the observation that isoniazid arose first in all 4 cases is 
in agreement with results from previously published genomic 
studies from South Africa [27] and South America [31].
Novel Predicted Drug Resistance Mutations in India
Recent sequencing studies suggest that known mutations can 
account for the majority of phenotypic resistance [16–19] but 
have been far from exhaustive in representing global M. tubercu-
losis diversity. To assess how well-known mutations explain drug 
resistance in India, we calculated how well 2 previously published 
Figure 1. Phylogeny of all 223 newly sequenced strains, together with 243 previously published strains from Comas et al. Branches are colored according to lineage, and 
outer ticks are colored according to dataset of origin and geographic location. For each strain, we performed variant detection relative to the M. tuberculosis H37Rv reference 
genome (see Detailed Methods) and identified a total of 67 722 variable SNP loci that were used to construct this phylogeny. .
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Figure 2. Clonal groups overlaid onto a phylogeny of all 223 newly sequenced strains from Southern India. Tree branches are colored by lineage, as in Figure 1. The central 
rings of dots indicate susceptibility phenotypes for isoniazid (11), rifampicin (11), ethambutol (11), and streptomycin (11) (from inside to outside, marked as “IRES”). A gray 
“Missing” mark indicates that no conclusive phenotype was available. Moving outward, the next ring is a numeric patient identifier, followed by clonal group ID (in red) and 
treatment center. Clonal groups are boxed in red. Treatment centers P01-P14 are in Tiruvallur, whereas all Madurai strains are from the Gov. Rajaji Hospital. Clonal groups 
D16 and D24 contained a strain that lacked patient information and were excluded from further analysis.
Table 2. Summary table of clonal groups of strains occurring in multiple patients.
Phenotypea Genotypeb
Notes
Clonal 
group
Treatment 
center Patient ID Strain ID Date INH EMB RIF STR INH EMB RIF STR
D28 P05 87 M1560 10/8/2002 R S S S S S S S Phenotypic DR 
change only132 M2010 4/22/2003 S S S S S S S S
D15 P02 124 M2343 9/17/2003 S S S - S S S S
166 M2342 9/17/2003 S S S S S S S S
D30 P09 142 M2129 7/3/2003 S S S S S S S S
143 M2128 7/1/2003 S S S S S S S S
D1 P14 30 M1272 11/9/2001 S S S S S S S S
71 M1425 7/9/2002 S S S S S S S S
D8 P05 36 M1294 3/6/2002 S S S S S S S S
91 M1638 11/8/2002 S S S S S S S S
M4 P01 54 M1393 5/21/2002 R S S S R S S S Genotypic evo-
lution, rpoB 
S450L
97 M1780 1/10/2003 R S R S R S R S
M2323 8/21/2003 R S R - R S R S
M2324 8/21/2003 R S R - R S R S
Abbreviation: DR, drug resistance.
aS, susceptible; R, resistant; -: missing information. Indicates drug susceptibility for isoniazid (INH), ethambutol (EMB), rifampicin (RIF) and streptomycin (STR)
bGenotypic resistance is determined based on the Cohen et al. set
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mutation lists explained phenotypic resistance in these isolates. 
These lists included (11) 1325 mutations explaining resistance to 
15 drugs [32] (Coll set) and (ii) a curated list of polymorphisms 
explaining resistance to eight drugs [27] (Cohen set; Table  3). 
The sensitivity to predict isoniazid resistance among strains from 
Southern India was 73% for the Coll set and 74% for the Cohen 
set. Overall, these sensitivities were significantly lower than those 
reported from an analysis of isolates from the United Kingdom, 
Sierra Leone, and South Africa (>85%) [17] but were similar to 
an earlier study from Southern India in which isoniazid resist-
ant strains had a lower frequency of known katG mutations [33]. 
The sensitivities for detecting rifampicin, streptomycin, and eth-
ambutol resistance (73%, 27–60%, and 50–80%, respectively) 
were also lower than those reported for other geographic regions 
by Walker et  al. (92%, 82%, and 82%, respectively) [17] and 
Desjardins et al. (>90%) [19], indicating that novel mechanisms 
may drive some drug resistance in India. Though novel rpoB 
and gidB mutations previously identified in Indian strains were 
not included in either list, neither mutation was present within 
this set of strains [20, 21]. Notably, 27% of rifampicin resistant 
strains lacked mutations in the resistance-determining region of 
rpoB, the basis for a widely used MDR-TB diagnostic [34, 35]. We 
confirmed that our results extended to other published mutation 
lists and that overall sensitivity was only marginally improved by 
including any mutation that would impact the resulting protein 
in genes associated with resistance (see Supplementary Note and 
Supplementary Figure 3).
To further examine cases of unexplained resistance, we first 
searched for potential novel mutations within genes previously 
implicated in resistance but not found in our mutation lists. Of 
the 9 strains with unexplained isoniazid resistance (Table  4; 
Supplementary Figure 4), one encoded the katG N138S muta-
tion, previously implicated in resistance but not present on 
either list [36]. Three strains contained mutations in 1 or more 
well-recognized resistance-determining targets, katG (A290P 
or L427P), fadE24 (R454S) or fabD (A159T), that had not pre-
viously been implicated in resistance but that were specific to 
resistant strains in this study (Table 4; Supplementary Figure 4). 
The remaining 4 strains lacked mutations in genes previously 
Table 3. Sensitivity and specificity for predicting phenotypic resistance using the Coll et al. and Cohen et al. lists of mutations
Drug Mutation set True Positivesa False Negatives False Positives True Negatives Ambiguousa Sensitivity Specificity
Isoniazid Coll 24 9 9 155 3 72.7% 94.5%
Cohen 25 9 5 159 2 73.5% 97.0%
Coll+Cohen 26 8 9 155 3 76.5% 94.5%
Rifampicin Coll 8 3 2 186 1 72.7% 98.9%
Cohen 8 3 1 187 1 72.7% 99.5%
Coll+Cohen 8 3 2 186 1 72.7% 98.9%
Streptomycin Coll 4 11 3 180 1 26.7% 98.4%
Cohen 9 6 7 177 1 60.0% 96.2%
Coll+Cohen 9 6 7 176 1 60.0% 96.2%
Ethambutol Coll 4 1 137b 57 2 80.0% 29.4%
Cohen 2 2 1 194 2 50.0% 99.5%
Coll+Cohen 4 1 137 57 3 80.0% 29.4%
aAmbiguous single-nucleotide polymorphism calls, with reads supporting a drug sensitive and a drug resistant genotype. These positions were excluded from the calculations for sensitivity 
and specificity.
bThe large number of false positives for streptomycin using the Coll dataset is due to the presence of the embB E378A mutation, which other publications suggest does not cause etham-
butol resistance. This mutation has been previously reported as a phylogenetic marker of lineage 1 of the ancestral MTBC, and this mutation is indeed present in most lineage 1 strains in 
this collection.
cAnalysis performed for 201 strains, after removing highly similar strains found within the same patient.
Table 4. Overview of phenotypic drug resistance not explained by either 
the mutations in the Coll et al. or Cohen et al. lists, or by mixed infections.
Drug Strain identifierb Categorya Descriptionc
Isoniazid M2139 Unexplained
M1560 Unexplained
M2259 Putative novel mutation fadE24 R454S
M1292 Putative novel mutation fabD A159T
M2360, M2361 Unexplained
M1948 Putative novel mutation katG A290P
M2131 Putative novel mutation katG L427P
M1545 Published mutation katG N138S [36]
Rifampicin M1292 Unexplained
M1324, M1325 Unexplained
H2438 Unexplained
Ethambutol M2084, M2085 Unexplained
Streptomycin M1270 Unexplained
M1762 Unexplained
M2116 Unexplained
M2206 Unexplained
M0013 Published mutation gidB R137W [17]
H3367 Published mutation rrs 877 [50]
a”Putative novel mutation” is defined by a non-synonymous mutation in a gene previously 
associated with drug resistance that was confined to phenotypically resistant isolates. 
“Unexplained” is defined when no new mutations were identified within genes previously 
associated with drug resistance. “Published mutation” is defined by mutations not present 
in either the Coll et al. or Cohen et al. mutation sets, but were previously associated with 
drug resistance.
bMultiple entries in the “strain identifier column correspond to same-patient strains with 
high identity
cPreviously published mutations, which were not included in either the Coll et al. or Cohen 
et al. datasets.
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associated with isoniazid resistance (Table  4; Supplementary 
Figure  4). For streptomycin, we identified mutations in gidB 
and rrs (gidB R137W and rrs 877) that may explain resistance 
for 2 of these strains. However, for all remaining isolates with 
unexplained resistance (4 rifampicin-, 2 ethambutol-, and 2 
streptomycin-resistant isolates), we could identify no additional 
candidate resistance-conferring mutations.
Presence of Mixed Infections Affects Ability to Predict Phenotype Based 
on Genotype
Recent studies suggest that tuberculosis patients can be infected 
with more than 1 M.  tuberculosis strain, including strains with 
differing resistance profiles [37–40]. We searched for evidence of 
mixed infections by, first, comparing repeat isolates from single 
patients and, second, examining variant data to identify evidence 
for conflicting base calls at sites implicated in resistance. Sixteen 
patients were sampled multiple times: 8 patients were sampled at 
different time points, and 14 were sampled multiple times on the 
same day. Consistent with rates from other studies [41, 42], none 
of the isolates collected from same-day, same-patient samplings 
belonged to different clonal groups (Supplementary Table  3), 
differing by only 0–6 SNPs, and indicating that same-day, with-
in-patient M.  tuberculosis sequence variation is low. With one 
exception, for longitudinally sampled patients, the first and last 
isolate(11) differed by only 2–8 SNPs, also supporting limited 
diversity. The exception (patient 38) was represented by 2 isolates 
differing by 301 SNPs, collected 6 months apart. Given slow muta-
tion rates [17, 27] and lack of recombination [43, 44] in M. tuber-
culosis, these 2 isolates were either transmitted to this patient at the 
initial point of infection or were acquired at different times.
Though we observed very consistent genotypes within 
the same patient, 3 longitudinally sampled patients exhib-
ited changes in drug resistance phenotypes over the study 
(Supplementary Table  3). However, we observed no accom-
panying genotypic change that could explain this change, 
even when we expanded our analysis to include any changes 
in known resistance targets. Because M.  tuberculosis cells are 
known to bundle [45], making it difficult to isolate single gen-
otypes in culture, we hypothesized that unexplained changes 
in phenotype may be due to mixed communities of genotypi-
cally distinct strains that we could detect through sequencing. 
However, we could find no evidence for ambiguity in any gene 
previously associated with drug resistance among these isolates.
Using the same strategy, we systematically examined all strains 
for examples of mixed infections that could help explain cases 
of unexplained resistance (Table  4). Fifteen strains had ambigu-
ous variant calls within genes known to be involved in resistance 
(Supplementary Table 4), including 7 strains with ambiguous calls at 
sites found within the Coll and Cohen sets (Table 3; Supplementary 
Table 4). In these cases, we observed additional ambiguous posi-
tions at >10 positions with similar allele ratios at other non–resist-
ance-associated sites, indicating mixed infections with nonclonal 
strains. One of these strains, M1961, contained a call of ‘ambigu-
ous’ at 2 known resistance sites found in the Coll and Cohen sets, 
as well as at 3 other sites within genes known to be involved in 
resistance. At each site, the major allele was observed 52–58% of 
the time (Supplementary Table 4). Although we detected strains 
having ambiguity at sites within drug resistance genes not present 
within the Cohen and Coll sets, none of these ambiguities could 
explain additional resistance for isolates in Table 4. Despite this, 
the fact that at least 7% of our strains had ambiguity within drug 
resistance genes, and that ambiguous sites were not taken into 
account when we calculated sensitivity and specificity of known 
mutations to explain resistance, underscores mixed infections as a 
confounder of genotype-based predictions of phenotypes.
DISCUSSION
Our study, focused on M.  tuberculosis from Southern India, 
expands the catalog of genetic diversity for the M.  tuberculo-
sis complex, particularly contributing to our understanding of 
lineage 1 and 3 strains that predominate in India, a region for 
which whole genome sequencing-based analyses of M. tubercu-
losis have been limited [46, 47]. In addition, our study provides 
insights into M. tuberculosis transmission patterns in Southern 
India, how these strains evolve drug resistance and provides a 
community resource for exploration of global M.  tuberculosis 
diversity, including the unique characteristics of lineages 1 and 3.
We observed highly localized cases of patient-to-patient 
transmission of strains (≤10 SNP differences) within individual 
treatment centers. Consistent with previous studies in India, 
this could indicate a need for focus on prevention of nosoco-
mial transmission [48]. However, we lacked sufficient metadata 
to determine whether transmission occurred within a hospital 
or community setting.
Though our strains were enriched for resistant isolates (56) 
compared to the overall incidence in India [10], including 21 
MDR-TB, we were only able to disambiguate the relative order-
ing of acquisition of resistance for a small number of pairs. 
Though further studies will be needed to confirm our results, 
they were consistent with previous work showing that isoniazid 
resistance arises first and serves as a precursor for MDR-TB in 
other world regions [27, 31].
A substantial fraction of phenotypic drug resistance in our 
sample could be explained by known mechanisms, consistent 
with studies in other lineages [16–19]. However, we observed 
that lists of known mutations performed less well in predict-
ing phenotypic drug resistance for Indian strains than for other 
regions [17, 33]. That we could not explain the cause of resistance 
for a quarter (14 of 56) of strains may not be surprising given 
that current catalogs of drug resistance mutations rely predom-
inantly upon data from other lineages. Though enriched for 
drug resistance, our data set contained only a small number of 
resistant isolates—particularly for ethambutol, rifampicin, and 
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streptomycin—which may impact the reliability of our sensitivity 
and specificity calculations for larger collections and also makes 
identifying novel mechanisms outside of known targets difficult.
Our effort did reveal several possible explanations for unex-
plained resistance within known targets. First, we identified 
mutations—katG A290P, katG L427P, fadE24 R454S, and fabD 
A159T—that should be experimentally prioritized for assessing 
their role in resistance. These add to the list of mutations previ-
ously identified as special to Indian strains [20, 21]. We did not 
find previously identified special resistance mutations among 
isolates from this collection, which could be explained by the fact 
that our study was small relative to the total number of resistant 
cases in India, and that it was also geographically constrained.
Second, careful examination of ambiguous base calls revealed 
that some patients harbored mixed infections of sensitive and 
resistant genotypes, impacting 7% of the strains we examined. 
However, even after accounting for the possibility of mixed 
infections at additional positions within genes involved in drug 
resistance, there were still 14 strains with unexplained resistance. 
Of the patients harboring these strains, 4 defaulted on treatment, 
which could have contributed to the development of resistance, 
and four were classified as “treatment failure.” Further studies are 
needed to examine whether these discrepancies are due to novel 
resistance mechanisms, the existence of mixed communities 
undetectable with our approach, phenotyping error, or alterna-
tive intrinsic mechanisms of resistance, such as the permeability 
of the cell wall and efflux pumps, which can vary between strains 
due to factors such as variable expression of genes [49].
Ultimately, the identification of putative novel resistance con-
ferring mutations, paired with the higher rate of unexplained 
resistance, highlights the challenges for diagnosing drug resist-
ance in India. Our findings raise the possibility that molecu-
lar diagnostics for tuberculosis drug resistance may need to 
be tailored for India. For instance, GeneXpert MTB/RIF [34], 
the front-line diagnostic used worldwide, relies on rifampicin 
resistance mutations to detect drug resistance [34], whereas 
in our study, we observed cases of rifampicin resistance of 
unknown cause. In addition, other commercially available 
diagnostics, such as Hain MTBDRplus (http://www.hain-lifes-
cience.de/en/products/microbiology/mycobacteria/tubercu-
losis/genotype-mtbdrplus.html), and Hain MTBDRsl (http://
www.hain-lifescience.de/en/products/microbiology/mycobac-
teria/tuberculosis/genotype-mtbdrsl.html) would also not have 
detected resistance for strains in Table 4. Larger whole-genome 
sequencing studies of strains from India are needed to establish 
patterns of lineage 1 and 3 specific mutations and to determine 
the utility of developing novel diagnostics specific for strains 
circulating in India.
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